Endicott JA - Search Results

1

Structure-based design of 2-arylamino-4-cyclohexylmethoxy-5-nitroso-6-aminopyrimidine inhibitors of cyclin-dependent kinase 2.

Marchetti F, Sayle KL, Bentley J, Clegg W, Curtin NJ, Endicott JA, Golding BT, Griffin RJ, Haggerty K, Harrington RW, Mesguiche V, Newell DR, Noble ME, Parsons RJ, Pratt DJ, Wang LZ, Hardcastle IR. Marchetti F, et al. Among authors: endicott ja. Org Biomol Chem. 2007 May 21;5(10):1577-85. doi: 10.1039/b703241b. Epub 2007 Apr 23. Org Biomol Chem. 2007. PMID: 17571187

2

The crystal structure of cyclin A.

Brown NR, Noble ME, Endicott JA, Garman EF, Wakatsuki S, Mitchell E, Rasmussen B, Hunt T, Johnson LN. Brown NR, et al. Among authors: endicott ja. Structure. 1995 Nov 15;3(11):1235-47. doi: 10.1016/s0969-2126(01)00259-3. Structure. 1995. PMID: 8591034 Free article.

3

Protein kinase inhibition by staurosporine revealed in details of the molecular interaction with CDK2.

Lawrie AM, Noble ME, Tunnah P, Brown NR, Johnson LN, Endicott JA. Lawrie AM, et al. Among authors: endicott ja. Nat Struct Biol. 1997 Oct;4(10):796-801. doi: 10.1038/nsb1097-796. Nat Struct Biol. 1997. PMID: 9334743

4

The cyclin box fold: protein recognition in cell-cycle and transcription control.

Noble ME, Endicott JA, Brown NR, Johnson LN. Noble ME, et al. Among authors: endicott ja. Trends Biochem Sci. 1997 Dec;22(12):482-7. doi: 10.1016/s0968-0004(97)01144-4. Trends Biochem Sci. 1997. PMID: 9433129 Review.

5

Structural principles in cell-cycle control: beyond the CDKs.

Endicott JA, Noble ME. Endicott JA, et al. Structure. 1998 May 15;6(5):535-41. doi: 10.1016/s0969-2126(98)00055-0. Structure. 1998. PMID: 9634691 Free article. Review.

6

Effects of phosphorylation of threonine 160 on cyclin-dependent kinase 2 structure and activity.

Brown NR, Noble ME, Lawrie AM, Morris MC, Tunnah P, Divita G, Johnson LN, Endicott JA. Brown NR, et al. Among authors: endicott ja. J Biol Chem. 1999 Mar 26;274(13):8746-56. doi: 10.1074/jbc.274.13.8746. J Biol Chem. 1999. PMID: 10085115 Free article.

7

Chemical inhibitors of cyclin-dependent kinases: insights into design from X-ray crystallographic studies.

Noble ME, Endicott JA. Noble ME, et al. Among authors: endicott ja. Pharmacol Ther. 1999 May-Jun;82(2-3):269-78. doi: 10.1016/s0163-7258(98)00051-5. Pharmacol Ther. 1999. PMID: 10454204 Review.

8

The structural basis for specificity of substrate and recruitment peptides for cyclin-dependent kinases.

Brown NR, Noble ME, Endicott JA, Johnson LN. Brown NR, et al. Among authors: endicott ja. Nat Cell Biol. 1999 Nov;1(7):438-43. doi: 10.1038/15674. Nat Cell Biol. 1999. PMID: 10559988

9

Cyclin-dependent kinases: inhibition and substrate recognition.

Endicott JA, Noble ME, Tucker JA. Endicott JA, et al. Curr Opin Struct Biol. 1999 Dec;9(6):738-44. doi: 10.1016/s0959-440x(99)00038-x. Curr Opin Struct Biol. 1999. PMID: 10607671 Review.

10

Cyclin-dependent kinase inhibition by new C-2 alkynylated purine derivatives and molecular structure of a CDK2-inhibitor complex.

Legraverend M, Tunnah P, Noble M, Ducrot P, Ludwig O, Grierson DS, Leost M, Meijer L, Endicott J. Legraverend M, et al. J Med Chem. 2000 Apr 6;43(7):1282-92. doi: 10.1021/jm9911130. J Med Chem. 2000. PMID: 10753466

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

102 results

Search Page